AI Governance
Pharma Does Not Need a New AI Governance Religion
AI governance in pharma is not a greenfield problem. It is a quality-systems extension problem — mapping AI agent management maturity to QMS maturity that already exists.
Most industries are still working out how to implement and govern AI. Pharma is in a different position. In GMP environments, governance is already an operating discipline. The Pharmaceutical Quality System, supported by Quality by Design, Critical to Quality attributes, and process parameter control, already provides a practical foundation for governing a new type of worker: the AI agent. The opportunity is not to invent a parallel governance stack. It is to map AI agent management maturity to quality management maturity, and run it with the same rigour already applied to every other regulated process.
Pharma already speaks the language
Recent agentic-AI direction from major platform vendors emphasises lifecycle controls, trust boundaries, layered verification, and continuous evaluation for AI agents. For pharma teams, that is not unfamiliar territory — it maps closely to existing GMP operating logic: define intended use and quality objectives up front; control the process conditions that materially influence quality outcomes; verify continuously against defined critical-to-quality attributes; and act on drift with corrective action when performance deviates from approved operating ranges. That is already how mature quality systems are managed. The vocabulary of AI agent governance and GMP governance are, in practice, the same.
Governance is a systems view, not a model check
When an AI agent participates in a regulated workflow, governance cannot rely on isolated model checks alone — the full operating system has to be brought under control:
- Role and intended use: a clearly defined function within the regulated workflow, with documented decision boundaries and scope limitations.
- Approved data and tool boundaries: explicit allow-lists for data sources, retrieval scope, and tool permissions, controlled rather than assumed.
- Execution controls: runtime configuration, model version, prompt version, and fallback routing treated as controlled parameters.
- Human review points: mandatory review gates at compliance-critical decision points, with evidence of review captured.
- Evidence and traceability: audit-ready provenance records for every agent output used in a regulated decision.
- Change control and revalidation: formal lifecycle gates for model updates, prompt changes, and configuration modifications.
That is a systems view, and it aligns directly with the quality-system principles already embedded in mature pharmaceutical organisations.
A five-level maturity map
AI agent management maturity maps directly to QMS maturity levels, with a characteristic governance signal at each stage:
| Level | QMS analogue | Typical signal |
|---|---|---|
| 1 — Ad hoc | Reactive quality posture | Inconsistent output quality, low traceability |
| 2 — Documented | Basic defined system | Repeatable process, fragile under variation |
| 3 — Controlled | Managed quality system | Stable operation with auditable evidence |
| 4 — Predictive | Capable quality system | Risks detected before quality failure occurs |
| 5 — Optimised | Continuous-improvement maturity | Sustained performance improvement, controlled risk |
Applying Quality by Design to agents
Before any AI agent enters a regulated workflow, teams can define an Agent Quality Target Profile — the agent equivalent of a product quality target profile: intended role, decision boundaries, required evidence outputs, acceptable failure modes, and mandatory human checkpoints. Critical-to-quality attributes for an agent include output accuracy against approved references, provenance completeness of retrieved information, explainability at the required review depth, and timeliness within approved process windows. Critical process parameters — model version, prompt version, retrieval scope, tool permissions, confidence thresholds, timeout and retry policy — are the controlled inputs that materially influence those attributes, and treating them as informal settings rather than controlled parameters is where AI agent governance breaks down.
A stage-gated rollout
Teams do not need to reach maturity level 5 before deploying AI agents responsibly. A structured rollout mirrors the phased approach used in process validation and CAPA management: map current maturity, apply Quality by Design and critical-to-quality frameworks to define and measure agent performance as a regulated process, verify continuously against defined attributes, and feed performance findings into CAPA-style improvement cycles over time.
The fastest path to safe AI adoption in GMP is to govern agents with the same discipline already used for any critical process. The bedrock for AI agent governance already exists inside mature quality systems — the work now is structured adaptation, not reinvention.